Viralytics
Follow
Get notifications in MyBN when activity occurs.
Upgrade your subscription to use this feature.
Viralytics is focused on the development and commercialisation of oncolytic immunotherapies that harness the power of certain viruses to preferentially infect and kill cancer cells. The lead product candidate is CAVATAKTM, a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21), now being evaluated in Phase 1 and 2 clinical trials.
Contact Details
Suite 305, Level 3, 66 Hunter Street, SYDNEY NSW 2000
02 9988 4000
Company Activity
| NEWS: Tagged in Where markets meet medicine; a biotech entrepreneur at the tip of the spear | 14 Feb 2022 |
News Articles
Related Information
Notable People
| Name | Position | Year Started |
|---|---|---|
| Chief Executive Officer | 2013 |
| Non-Executive Chair | 2007 |
| Non-Executive Director | 2011 |
Past People
| Name | Position | Year Started | Year Ended |
|---|---|---|---|
| Peter Turvey | Non-Executive Director | 2014 | 2018 |
| Peter Molloy | Non-Executive Director | 2008 | 2014 |
| Catherine Officer | Company Secretary | 2013 | 2014 |
| Bryan Dulhunty | Managing Director | 2005 | 2012 |
| Stephen Goodall | Chief Operating Officer | 2008 | 2011 |
ECM Deals
| Date | Company | Transaction Type | Total Value | |
|---|---|---|---|---|
| 02/02/12 | Viralytics | Share purchase plan | $3.5m | >> |
